Cyclo Therapeutics, Inc.
CYTHDelisted Mar 26, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000922247
Cyclo Therapeutics, Inc. was delisted on Mar 26, 2025; its insiders filed their last Form 4 on Mar 3, 2025; 22 institutions reported holding it in 13F filings for Q4 2024, worth $1.33M in total; no superinvestor held it.
13F holders, Q2 2024
Institutional positions in Cyclo Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 22
- 0 vs. Q1 2024
- Shares held
- 2.24M
- +73.3K (+3.4%) vs. Q1 2024
- Total value
- $2.84M
- −$166.3K (−5.5%) vs. Q1 2024
- New holders
- 1
- 5 more added
- Sold out
- 1
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CYTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 22 | $1.33M |
| Q3 2024 | 19 | $1.80M |
| Q2 2024 | 22 | $2.84M |
| Q1 2024 | 22 | $3.01M |
| Q4 2023 | 23 | $2.06M |
| Q3 2023 | 17 | $682.7K |
| Q2 2023 | 14 | $725.2K |
| Q1 2023 | 16 | $820.2K |
| Q4 2022 | 15 | $1.83M |
| Q3 2022 | 12 | $768.0K |
| Q2 2022 | 13 | $794.0K |
| Q1 2022 | 13 | $1.38M |
| Q4 2021 | 15 | $1.71M |
| Q3 2021 | 13 | $2.23M |
| Q2 2021 | 12 | $2.70M |
| Q1 2021 | 9 | $585.0K |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Cyclo Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EPIQ Capital Group, LLC | 817,270 | $1.04M | 0.37% | −36,545−4.3% | Reduced |
| Founders Fund V Management, LLC | 480,708 | $610.5K | 72.16% | 00.0% | Unchanged |
| Vanguard Group Inc | 446,573 | $567.1K | 0.00% | +49,915+12.6% | Added |
| Geode Capital Management, LLC | 175,418 | $222.8K | 0.00% | +15,669+9.8% | Added |
| Founders Fund VI Management, LLC | 110,023 | $139.7K | 100.00% | 00.0% | Unchanged |
| BlackRock Inc. | 59,510 | $75.6K | 0.00% | +22,384+60.3% | Added |
| State Street Corp | 39,530 | $50.2K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 24,670 | $31.3K | 0.00% | +24,670 | New |
| Northern Trust Corp | 21,722 | $27.6K | 0.00% | −19−0.1% | Reduced |
| Wealth Enhancement Advisory Services, LLC | 20,400 | $25.9K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 13,356 | $17.0K | 0.00% | −8,400−38.6% | Reduced |
| UBS Group AG | 12,053 | $15.3K | 0.00% | +7,225+149.6% | Added |
| Tower Research Capital LLC (TRC) | 4,999 | $6.35K | 0.00% | −1,583−24.1% | Reduced |
| Wells Fargo & Company | 4,391 | $5.58K | 0.00% | −174−3.8% | Reduced |
| Princeton Global Asset Management LLC | 3,766 | $4.78K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,031 | $1.31K | 0.00% | −6−0.6% | Reduced |
| Royal Bank of Canada | 746 | $1.00K | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 210 | $266 | 0.00% | +183+677.8% | Added |
| JPMorgan Chase & Co | 153 | $194 | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 90 | $114 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 67 | $85 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 21 | $27 | 0.00% | 00.0% | Unchanged |
| Catalyst Funds Management Pty Ltd | 0 | $0 | 0.00% | −67−100.0% | Sold out |